Ieq Capital LLC Purchases New Shares in REGENXBIO Inc. $RGNX

Ieq Capital LLC purchased a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the first quarter, HoldingsChannel reports. The fund purchased 50,969 shares of the biotechnology company’s stock, valued at approximately $364,000.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. increased its position in REGENXBIO by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock worth $24,832,000 after acquiring an additional 487,036 shares during the period. Millennium Management LLC increased its position in REGENXBIO by 406.3% during the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock worth $10,222,000 after acquiring an additional 1,061,187 shares during the period. Balyasny Asset Management L.P. increased its position in REGENXBIO by 6.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock worth $9,176,000 after acquiring an additional 66,993 shares during the period. Dimensional Fund Advisors LP increased its position in REGENXBIO by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock worth $9,054,000 after acquiring an additional 21,234 shares during the period. Finally, 22NW LP bought a new position in REGENXBIO during the first quarter worth about $4,781,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Stock Performance

REGENXBIO stock opened at $9.71 on Friday. REGENXBIO Inc. has a 52 week low of $5.03 and a 52 week high of $13.48. The stock has a market capitalization of $490.45 million, a P/E ratio of -2.82 and a beta of 1.17. The stock has a fifty day moving average of $8.65 and a 200-day moving average of $8.17.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. On average, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analysts Set New Price Targets

RGNX has been the subject of several analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Friday, August 8th. Barclays dropped their price objective on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of REGENXBIO in a report on Tuesday, August 19th. Royal Bank Of Canada dropped their price objective on REGENXBIO from $21.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Finally, Wall Street Zen cut REGENXBIO from a “hold” rating to a “strong sell” rating in a report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.38.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.